CoChat
Sign Up
Cited by 82Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCancer, Lipids, and Metabolism

Statins and risk of type 2 diabetes: mechanism and clinical implications

Open access
Laakso, Markku, Fernandes Silva, Lilian·2023·Frontiers in Endocrinology
DOI 10.3389/fendo.2023.1239335PMC PMC10546337
Open this paper in CoChat — free accountOpen PDF

Abstract

Statins are widely used to prevent cardiovascular disease events. Cardiovascular diseases and type 2 diabetes are tightly connected since type 2 diabetes is a major risk factor for cardiovascular diseases. Additionally, cardiovascular diseases often precede the development of type 2 diabetes. These two diseases have common genetic and environmental antecedents. Statins are effective in the lowering of cardiovascular disease events. However, they have also important side effects, including an increased risk of type 2 diabetes. The first study reporting an association of statin treatment with the risk of type 2 diabetes was the WOSCOPS trial (West of Scotland Coronary Prevention Study) in 2001. Other primary and secondary cardiovascular disease prevention studies as well as population-based studies have confirmed original findings. The purpose of our review is to examine and summarize the most important findings of these studies as well as to describe the mechanisms how statins increase the risk of type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1239335

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 82

  1. [1]Fernandes Silva L Vangipurapu J Laakso M. The "Common Soil Hypothesis" revisited - risk tactors for type 2 diabetes and cardiovascular disease. Metabolites (2021) 11(10): 691. doi: 10.3390/metabo11100691 34677406 PMC8540397 · DOI
  2. [2]Swerdlow DI Hingorani AD Humphries SE. Genetic risk factors and Mendelian randomization in cardiovascular disease. Curr Cardiol Rep (2015) 17: 33. doi: 10.1007/s11886-015-0584-x 25894797 · DOI
  3. [3]Gill D Zuber V Dawson J Pearson-Stuttard J Carter AR Sanderson E. Risk factors mediating the effect of body mass index and waist-to-hip ratio on cardiovascular outcomes: Mendelian randomization analysis. Int J Obes (2021) 45: 1428–38. doi: 10.1038/s41366-021-00807-4 PMC8236409 34002035 · DOI
  4. [4]Aikens RC Zhao W Saleheen D Reilly MP Epstein SE Tikkanen E. Systolic blood pressure and risk of type 2 diabetes: A Mendelian randomization study. Diabetes (2017) 66: 543–50. doi: 10.2337/db16-0868 PMC5248987 27702834 · DOI
  5. [5]Yuan S Larsson SC. A causal relationship between cigarette smoking and type 2 diabetes mellitus: A Mendelian randomization study. Sci Rep (2019) 9: 19342. doi: 10.1038/s41598-019-56014-9 31852999 PMC6920406 · DOI
  6. [6]Zanetti D Gustafsson S Assimes TL Ingelsson E. Comprehensive investigation of circulating biomarkers and their causal role in atherosclerosis-related risk factors and clinical events. Circ Genom Precis Med (2020) 13: e002996. doi: 10.1161/CIRCGEN.120.002996 33125266 PMC8202726 · DOI
  7. [7]Ross S Gerstein H Paré G. The genetic link between diabetes and atherosclerosis. Can J Cardiol (2018) 34(5): 565–74. doi: 10.1016/j.cjca.2018.01.016 29731020 · DOI
  8. [8]Zhao W Rasheed A Tikkanen E Lee J-J Butterworth AS Howson JMM. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet (2017) 49(10): 1450–57. doi: 10.1038/ng.3943 PMC5844224 28869590 · DOI
  9. [9]Roelof A Smit J Trompet S Leong A Goodarzi MO Postmus I. Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. Pharmacogenomics J (2020) 20(3): 462–70. doi: 10.1038/s41397-019-0125-x PMC7260089 31801993 · DOI
  10. [10]Kearney PM Blackwell L Collins R Keech A Simes J Peto R. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 371: 117–25. doi: 10.1016/S0140-6736(08)60104-X 18191683 · DOI · Paper page
  11. [13]Baigent C Blackwell L Emberson J Holland LE Reith C Bhala N. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 376: 1670–81. doi: 10.1016/S0140-6736(10)61350-5 PMC2988224 21067804 · DOI · Paper page
  12. [14]Fernandes Silva L Ravi R Vangipurapu J Laakso M. Metabolite signature of simvastatin treatment involves multiple metabolic pathways. Metabolites (2022) 12: 753. doi: 10.3390/metabo12080753 36005625 PMC9414498 · DOI
  13. [15]Chogtu B Magazine R Baily KL. Statin use and risk of diabetes mellitus. World J Diabetes (2015) 6: 352–7. doi: 10.4239/wjd.v6.i2.352 PMC4360430 25789118 · DOI
  14. [16]Agarwala A Kulkarni S Maddox T. The association of statin therapy with incident diabetes: evidence, mechanisms, and recommendations. Curr Cardiol Rep (2018) 20(7): 50. doi: 10.1007/s11886-018-0995-6 29779165 · DOI
  15. [17]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care (2006) 29(Suppl 1): S43–8. 16373932
  16. [18]Laakso M Kuusisto J. Diabetes secondary to treatment with statins. Curr Diabetes Rep (2017) 17: 10. doi: 10.1007/s11892-017-0837-8 28155189 · DOI
  17. [19]Freeman DJ Norrie J Sattar N Neely RD Cobbe SM Ford I. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 103: 357–62. doi: 10.1161/01.CIR.103.3.357 11157685 · DOI · Paper page
  18. [20]Shepherd J Blauw GJ Murphy MB Bollen EL Buckley BM Cobbe SM. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360(9346): 1623–30. doi: 10.1016/S0140-6736(02)11600-X 12457784 · DOI · Paper page
  19. [21]Sabatine MS Wiviott SD Morrow DA McCabe CH Canon CP. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation (2004) 110:Suppl: S834. doi: 10.7860/JCDR/2017/23741.9427 · DOI
  20. [22]de Lemos JA Blazing MA Wiviott SD Brady WE White HD Fox KA. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J (2004) 25(19): 1688–94. doi: 10.1016/j.ehj.2004.06.028 15451146 · DOI
  21. [25]Preiss D Seshasai SR Welsh P Murphy SA Ho JE Waters DD. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 305: 2556–64. doi: 10.1001/jama.2011.860 21693744 · DOI · Paper page
  22. [27]Thakker D Nair S Pagada A Zamdade V Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf (2016) 25: 1131–49. doi: 10.1002/pds.4020 27277934 · DOI
  23. [28]Sattar NA Ginsberg H Ray K Chapman MJ Arca M Averna M. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler (2014) Suppl:15(1): 1– 15. doi: 10.1016/j.atherosclerosissup.2014.04.001 24840509 · DOI
  24. [29]Waters DD Ho JE DeMicco DA Breazna A Arsenault BJ Wun C-C. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol (2011) 57(14): 1535–45. doi: 10.1016/j.jacc.2010.10.047 21453832 · DOI · Paper page
  25. [31]Leung Ong K Barter PB Water DD. Cardiovascular drugs that increase the risk of new-onset diabetes. Am Heart J (2014) 167: 421–8. doi: 10.1016/j.ahj.2013.12.025 24655688 · DOI
  26. [32]Zhou Y Yuan Y Cai R-R Huang Y Xia W-O Yang Y. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother (2013) 14(12): 1575–84. doi: 10.1517/14656566.2013.810210 23826679 · DOI
  27. [33]Cui JY Zhou RR Han S Wang TS Wang LQ Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: a network meta-analysis. J Clin Pharm Ther (2018) 43(4): 556–70. doi: 10.1111/jcpt.12690 29733433 · DOI
  28. [34]Erqou S Lee CC Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia (2014) 57(12): 2444–52. doi: 10.1007/s00125-014-3374-x 25245638 · DOI · Paper page
  29. [35]Alvarez-Jimenez L Morales-Palomo F Moreno-Cabañas A Ortega JF Mora-Rodríguez R. Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis. Eur J Pharmacol (2023) 947: 175672. doi: 10.1016/j.ejphar.2023.175672 36965747 · DOI · Paper page
  30. [36]Mansi IA Chansard M Lingvay I Zhang S Halm EA Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med (2022) 181: 1– 14. doi: 10.1001/jamainternmed.2021.5714 PMC8491130 34605849 · DOI · Paper page
  31. [37]Zaharan NL Williams D Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol (2013) 75: 1118–24. doi: 10.1111/j.1365-2125.2012.04403.x PMC3612730 22845189 · DOI
  32. [39]Djoussé L Song RJ Cho K Gaziano JM Gagn DR. Association of statin therapy with incidence of type 2 diabetes among US Veterans. J Clin Cardiol Cardiovasc Ther (2019) 1(1). doi: 10.31546/JCCCVT.1002 PMC6816272 31660540 · DOI
  33. [40]Cederberg H Stančáková A Yaluri N Modi S Kuusisto J Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6-year follow-up study of the METSIM cohort. Diabetologia (2015) 58: 1109–17. doi: 10.1007/s00125-015-3528-5 25754552 · DOI
  34. [41]Laakso M Kuusisto J Stančáková A Kuulasmaa T Pajukanta P Lusis AJ. The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. J Lipid Res (2017) 58(3): 481–93. doi: 10.1194/jlr.O072629 PMC5335588 28119442 · DOI
  35. [42]Ahmadizar F Ochoa-Rosales C Glisic M Franco OH Muka T Stricker BH. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol (2019) 85: 993– 1002. doi: 10.1111/bcp.13898 30838685 PMC6475692 · DOI
  36. [43]Crandall JP Mather K Rajpathak SN Goldberg RB Watson K Foo S. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care (2017) 5(1): e000438. doi: 10.1136/bmjdrc-2017-000438 PMC5652620 29081977 · DOI · Paper page
  37. [44]Engeda JC Stackhouse A White M Rosamond WD Lhachimi SK Lund JL. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. Diabetes Res Clin Pract (2019) 151: 96– 105. doi: 10.1016/j.diabres.2019.04.005 30954511 PMC6544490 · DOI
  38. [45]Niemi M Pasanen MK Neuvonen PJ. Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev (2011) 63: 157–81. doi: 10.1124/pr.110.002857 21245207 · DOI
  39. [46]Romaine SPR Bailey KM Hall AS Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J (2010) 10(1): 1– 11. doi: 10.1038/tpj.2009.54 19884908 · DOI
  40. [48]Fernandes Silva L Ravi R Vangipurapu J Oravilahti A Laakso M. Effects of SLCO1B1 genetic variant on metabolite profile in participants on simvastatin treatment. Metabolites (2022) 12(12): 1159. doi: 10.3390/metabo12121159 36557197 PMC9785662 · DOI
  41. [49]Goldstein JL Brown MS. Regulation of the mevalonate pathway. Nature (1990) 343: 425–30. doi: 10.1038/343425a0 1967820 · DOI · Paper page
  42. [50]Swerdlow DI Preiss D Kuchenbaecker KB Holmes MV Engmann JEL Shah T. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials. Lancet (2015) 385: 351–61. doi: 10.1016/S0140-6736(14)61183-1 PMC4322187 25262344 · DOI · Paper page
  43. [51]Yang G Schooling CM. Statins, type 2 diabetes, and body mass index: a univariable and multivariable Mendelian randomization study. J Clin Endocrinol Metab (2023) 108(2): 385–96. doi: 10.1210/clinem/dgac562 36184662 · DOI
  44. [52]Sattar N. Statins and diabetes: what are the connections? Best Pract Res Clin Endocrinol Metab (2023) 37: 101749. doi: 10.1016/j.beem.2023.101749 36858834 · DOI
  45. [53]Carmena R Betteridge DJ. Diabetogenic action of statins: mechanisms. Curr Atheroscler Rep (2019) 21: 23. doi: 10.1007/s11883-019-0780-z 31037345 · DOI
  46. [54]Abbasi F Lamendola C Harris CS Harris V Tsai M-S Tripathi P. Statins are associated with increased insulin resistance and secretion. Arterioscler Thromb Vasc Biol (2021) 41(11): 2786–97. doi: 10.1161/ATVBAHA.121.316159 PMC8551023 34433298 · DOI · Paper page
  47. [55]Brown MS Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science (1974) 185: 61–3. doi: 10.1126/science.185.4145.61 4366052 · DOI
  48. [56]Climent E Pérez-Calahorra S Marco-Benedí V Plana N Sánchez R Ros E. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Sci Rep (2017) 7(1): 5596. doi: 10.1038/s41598-017-06101-6 28717233 PMC5514105 · DOI
  49. [57]Preiss D Sattar N. Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA (2015) 313: 1016–7. doi: 10.1001/jama.2015.1275 25756436 · DOI
  50. [58]Vohl MC Gaudet D Moorjani S Tremblay G Perron P Gagne C. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest (1997) 27: 366–73. doi: 10.1046/j.1365-2362.1997.1250669.x 9179542 · DOI
  51. [59]Fall T Xie W Poon W Yaghootkar H Mägi R Consortium GENESIS. Using genetic variants to assess the relationship between circulating lipids and type 2 diabetes. Diabetes (2015) 64: 2676–84. doi: 10.2337/db14-1710 25948681 · DOI
  52. [60]Lotta LA Sharp SJ Burgess S Perry JRB Stewart ID Willems SM. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA (2016) 316: 1383–91. doi: 10.1001/jama.2016.14568 PMC5386134 27701660 · DOI · Paper page
  53. [61]Besseling J Kastelein JJP Defesche JC Hutten BA Hovingh KG. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA (2015) 313: 1029–36. doi: 10.1001/jama.2015.1206 25756439 · DOI
  54. [62]Yu Q Chen Y Xu C-B. Statins and new-onset diabetes mellitus: LDL receptor may provide a key link. Front Pharmacol (2017) 8: 372. doi: 10.3389/fphar.2017.00372 28659805 PMC5468445 · DOI
  55. [64]Fulcher J Mihaylova B O’Connell R Emberson J Blackwell L Reith C. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet (2019) 393(10170): 407–15. doi: 10.1016/S0140-6736(18)31942-1 PMC6429627 30712900 · DOI · Paper page
  56. [65]White J Swerdlow DI Preiss D Fairhurst-Hunter Z Keating BJ Asselbergs FW. Lipid fractions and contrasting risks of coronary artery disease and diabetes. JAMA Cardiol (2016) 1: 692–99. doi: 10.1001/jamacardio.2016.1884 PMC5642865 27487401 · DOI · Paper page
  57. [66]González-Lleó AM Sánchez-Hernández RM Boronat M Wägner AM. Diabetes and familial hypercholesterolemia: interplay between lipid and glucose metabolism. Nutrients (2022) 14(7): 1503. doi: 10.3390/nu14071503 35406116 PMC9002616 · DOI
  58. [67]Stancáková A Javorský M Kuulasmaa T Haffner SM Kuusisto J Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 58(5): 1212–21. doi: 10.2337/db08-1607 PMC2671053 19223598 · DOI · Paper page
  59. [68]Baker WL Talati R White CM Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract (2010) 87: 98– 107. doi: 10.1016/j.diabres.2009.10.008 19913318 · DOI
  60. [69]Laakso M Fernandes Silva L. Genetics of type 2 diabetes: past, present, and future. Nutrients (2022) 14: 3201. doi: 10.3390/nu14153201 35956377 PMC9370092 · DOI
  61. [70]Perego C Da Dalt L Pirillo A Galli A Catapano AL Norata GD. Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim Biophys Acta Mol Basis Dis (2019) 1865: 2149–56. doi: 10.1016/j.bbadis.2019.04.012 31029825 · DOI
  62. [71]Zhu Y Liu Q Zhou Z Ikeda Y. PDX1, neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther (2017) 8: 240. doi: 10.1186/s13287-017-0694-z 29096722 PMC5667467 · DOI
  63. [72]Takei S Nagashima S Takei A Yamamuro D Wakabayashi T Murakami A. β-cell-specific deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase causes overt diabetes due to reduction of β-cell mass and impaired insulin secretion. Diabetes (2020) 69: 2352–63. doi: 10.2337/db19-0996 32796082 · DOI
  64. [73]Kruit JK Kremer PH Dai L Ruddle P de Haan W Brunham LR. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia (2010) 53: 1110–19. doi: 10.1007/s00125-010-1691-2 20229095 · DOI
  65. [74]Galicia-Garcia U Jebari S Larrea-Sebal A Uribe KB Siddiqi H Ostolaza H. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci (2020) 21: 4725. doi: 10.3390/ijms21134725 32630698 PMC7369709 · DOI
  66. [75]Yada T Nakata M Shiraishi T Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br J Pharmacol (1999) 126: 1205–13. doi: 10.1038/sj.bjp.0702397 PMC1565875 10205010 · DOI
  67. [76]Yaluri N Modi S López Rodríguez M Stančáková A Kuusisto J Kokkola T. Simvastatin impairs insulin secretion by multiple mechanisms in MIN6 cells. PloS One (2015) 10: e0142902. doi: 10.1371/journal.pone.0142902 26561346 PMC4641640 · DOI
  68. [77]Buldak L Machnik G Skudrzyk E Boldys A Maliglowka M Kosowski M. Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner. J Appl BioMed (2022) 20: 130–40. doi: 10.32725/jab.2022.015 36708718 · DOI
  69. [78]Merz SA Rabaglia ME Stock JB Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem (1993) 295: 31– 40. doi: 10.1042/bj2950031 PMC1134816 8216234 · DOI
  70. [79]Wang L Duan G Lu Y Pang S Huang X Jiang Q. The effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats. J Diabetes Res (2013) 274986: 74986. doi: 10.1155/2013/274986 PMC3647597 23671864 · DOI
  71. [80]Zhou J Li W Xie Q Hou Y Zhan S Yang X. Effects of simvastatin on glucose metabolism in mouse MIN6 cells. J Diabetes Res (2014) 2014: 376570. doi: 10.1155/2014/376570 24995341 PMC4065655 · DOI
  72. [81]Scattolini V Luni C Zambon A Galvanin S Gagliano O Dacian Ciubotaru C. Simvastatin rapidly and reversibly inhibits insulin secretion in intact single-islet cultures. Diabetes Ther (2016) 7: 679–93. doi: 10.1007/s13300-016-0210-y PMC5118248 27830474 · DOI
  73. [82]Mbikay M Sirois F Mayne J Wang G-S Chen A Dewpura T. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnorMalities. FEBS Lett (2010) 584(4): 701–6. doi: 10.1016/j.febslet.2009.12.018 20026049 · DOI
  74. [83]Grunwald SA Haafke S Grieben U Kassne U Steinhagen-Thiessen E Spuler S. Statins aggravate the risk of insulin resistance in human muscle. Int J Mol Sci (2022) 23: 2398. doi: 10.3390/ijms23042398 35216514 PMC8876152 · DOI
  75. [84]Sarsenbayeva A Nandi Jui B Fanni G Barbosa P Ahmed F Kristófi R. Impaired HMG-CoA reductase activity caused by genetic variants or statin exposure: impact on human adipose tissue, β-cells and metabolome. Metabolites (2021) 11: 574. doi: 10.3390/metabo11090574 34564389 PMC8468287 · DOI
  76. [85]Wang HJ Park JY Kwon O Choe EY Kim CH Hur KY. Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. Autophagy (2015) 11: 2089–101. doi: 10.1080/15548627.2015.1091139 PMC4824590 26389569 · DOI
  77. [86]Newgard CB An J Bain JR Muehlbauer MJ Stevens RD Lien LF. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 9: 311–26. doi: 10.1016/j.cmet.2009.02.002 PMC3640280 19356713 · DOI · Paper page
  78. [87]Bai X Long X Song F Chen B Sheng C Tang C. High doses of rosuvastatin induce impaired branched-chain amino acid catabolism and lead to insulin resistance. Exp Physiol (2023) 108(7): 961–74. doi: 10.1113/EP090305 PMC10988443 37139700 · DOI
  79. [88]Aguer C Colin S McCoin T Thrush AB Ono-Moore K McPherson R. Acylcarnitines: potential implications for skeletal muscle insulin resistance. FASEB J (2015) 29: 336–45. doi: 10.1096/fj.14-255901 PMC4285541 25342132 · DOI
  80. [89]Guasch-Ferré M Ruiz-Canela M Jun Li Y Zheng MB Wang DD Toledo E. Plasma acylcarnitines and risk of type 2 diabetes in a mediterranean population at high cardiovascular risk. J Clin Endocrinol Metab (2019) 04: 1508–19. doi: 10.1210/jc.2018-01000 PMC6435097 30423132 · DOI
  81. [90]Climent E Benaiges D Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med (2021) 8: 687585. doi: 10.3389/fcvm.2021.687585 34095267 PMC8172607 · DOI
  82. [91]Nielsen SF Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol (2014) 2(11): 894– 900. doi: 10.1016/S2213-8587(14)70173-1 25217178 · DOI · Paper page

Cited by

Sorted by citations

Authors
Laakso, M., & Fernandes Silva, L.
Affiliations
University of Eastern Finland (FI)
Corresponding author
Laakso, Markku
ORCID
Laakso, Markku
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2023-09-19
Volume
14
Pages
1239335-1239335
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2023.1239335
PMC
PMC10546337
OpenAlex
W4386893914
Cited by
82
References
9
Citations by year
2026: 28 · 2025: 33 · 2024: 20 · 2023: 1
FWCI
5.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
statins, type 2 diabetes, statin-induced diabetes, cardiovascular disease, adverse drug reactions, cardiovascular disease prevention
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review